Blier P, Bergeron R
Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
J Clin Psychopharmacol. 1995 Apr;15(2):106-9. doi: 10.1097/00004714-199504000-00005.
It is presently contraindicated to use the antimigraine drug sumatriptan with selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, or lithium. Consequently, many patients undergoing these pharmacotherapies for psychiatric disorders may not benefit from the therapeutic effect of sumatriptan in acute migraine attacks. Because sumatriptan does not appear to cross the blood-brain barrier and has a short half-life, it was deemed relatively safe to prescribe sumatriptan with antidepressant treatments. Fourteen patients receiving fluoxetine, fluvoxamine, sertraline, moclobemide, lithium, or buspirone did not experience significant side effects when they took oral sumatriptan for the relief of migraine on a total of 103 episodes. It is concluded that the combined use of sumatriptan with the above-mentioned antidepressant treatments may be safe.
目前，抗偏头痛药物舒马曲坦与选择性5-羟色胺再摄取抑制剂、单胺氧化酶抑制剂或锂盐联合使用是禁忌的。因此，许多正在接受这些精神疾病药物治疗的患者可能无法从舒马曲坦治疗急性偏头痛发作的疗效中获益。由于舒马曲坦似乎不能穿过血脑屏障且半衰期较短，所以认为将舒马曲坦与抗抑郁治疗联合使用相对安全。14名正在接受氟西汀、氟伏沙明、舍曲林、吗氯贝胺、锂盐或丁螺环酮治疗的患者，在总共103次口服舒马曲坦以缓解偏头痛发作时，未出现明显的副作用。结论是，舒马曲坦与上述抗抑郁治疗联合使用可能是安全的。
